Agenda – The BD&L Summit for Life Sciences

  • Day One
  • Day Two

Day One

 Monday, February 25

9:00AM – 9:45AM

Pfizer’s Innovation Ecosystem — Breakthrough Impact for Patients
Felice Shieh, Ph.D., MBA, Senior Director, External Science and Innovation, PFIZER

9:45AM – 11:00AM

Panel: Compare and Contrast Different Operating Models for Search and Evaluation to Advance Innovation
Brian Bronk, Ph.D., Head of External Innovation, Rare Diseases, SANOFI
Martin Picard, Ph.D., Vice President, Global Head Search, Evaluation and Due Diligence, MERCK KGAA
Mark E. Nuttall, Ph.D., Chief Business Officer, KYMERA THERAPEUTICS
Felice Shieh, Ph.D., MBA, Senior Director, External Science and Innovation, PFIZER

11:00AM – 11:45AM

Panel: Uncertainty, Challenges and Implications of Today’s Reimbursement Environment on the Deal-Making Landscape
Adam Kundzewicz, Ph.D., Global Head of Strategic Market Access Initiatives, BOEHRINGER INGELHEIM
Peter Trybus, Senior Corporate Counsel, Healthcare Law, Managed Care Practice Group, GENENTECH
Kristen B. Slaoui, Ph.D., Vice President, Head of Business Development, North America, Corporate Strategy and Development, GSK
Joel Sangerman, Chief Commercial Officer, CLICK THERAPEUTICS

11:45AM – 12:30PM

Panel: Consider the Risk Profile Associated With Different Sources and Mechanisms of Financing
Janice Bourque, Managing Director, Life Sciences, HERCULES CAPITAL
Jackie Spencer, Managing Director, Life Sciences and Healthcare, SILICON VALLEY BANK
Brian Axe, Principal, NOVAQUEST CAPITAL MANAGEMENT
Carolyn Ng, Ph.D., Principal, VERTEX VENTURES HC
Joel Herold, Chief Legal Officer and Chief Compliance Officer, DRI CAPITAL

12:30PM – 1:30PM

Luncheon

 

BUSINESS DEVELOPMENT

1:45PM – 2:30PM

Common Versus Best Practices in Navigating a Virtual Approach to Informing a Deal Decision

Mike Myers, Senior Director, Lilly Research Labs — Due Diligence, ELI LILLY

2:30PM – 3:15PM

The Role of Experimental Work Carried Out Under Material Transfer Agreements (MTAs) in the Context of Due Diligence

Niels P. Emmerich, Ph.D., Vice President, Global Head Search and Evaluation, ABBVIE

LEGAL/TRANSACTIONS

1:45PM – 2:30PM

Develop a Road Map for an Efficient and Comprehensive Intellectual Property Due Diligence Investigation

Philip Datlow, Director and Senior Counsel, Intellectual Property, BOEHRINGER INGELHEIM

2:30PM – 3:15PM

Effective IP Strategies (With a European Perspective)

Steven Gurney, Principal Associate and Patent Attorney, MARKS & CLERK
Will James, Partner and Solicitor, MARKS & CLERK

 

3:15PM – 3:45PM

Networking Break

 

3:45PM – 4:30PM

From Big to Small: How to Transition From Big Companies and Successfully Drive BD at a Start-Up Company

Lisa Beck, Vice President, Business Development and Alliance Management, BRII BIOSCIENCES
Behrad Derakhshan, Ph.D., Vice President, Head of Business Development, THERACON
Michah Zajic, Vice President, Corporate Development, MEIRAGTX
Zubin Bhagwagar, M.D., Ph.D., Global Program Lead, RALLYBIO
Matthew Batters, J.D., Executive Director, Transactions, Alliance Management, Business Development and Corporate Counsel, ARVINAS

4:30PM – 5:15PM

Holistic Approaches to Long-Term Business Development and Licensing

Kleem Chaudhary, Ph.D., Head, BD&L MS, AD, OPN, Platforms, BIOGEN

3:45PM – 4:30PM

Successfully Navigate Antitrust Aspects of Future Transactions

If you are interested in leading this session, please contact Michael Williams at mwilliams@exlevents.com.

4:30PM – 5:15PM

Case Study: Oversight of a Sale Process for Distressed Companies

Tom Lynch, Chief Administrative Officer, General Counsel and Secretary, OREXIGEN

 


Day Two

 Tuesday, February 26

8:00AM – 8:45AM

Continental Breakfast

 

BUSINESS DEVELOPMENT

9:00AM – 9:45AM

Lean Licensing: Seizing Opportunity Out of Market Misalignment

John Fair, Chief Business Officer, DARÉ BIOSCIENCE

9:45AM – 10:30AM

Integration of Alliance Management in the Deal-Making Process

Teresa Faria, Ph.D., Senior Director, Alliance Management, External Scientific Affairs, DAIICHI SANKYO

LEGAL/TRANSACTIONS

9:00AM – 9:45AM

Case Study: Spin on Spins — How Mallinckrodt Was Spun Out From Covidien

Rick Hoyt, Vice President, Business Development and Licensing, MALLINCKRODT

9:45AM – 10:30AM

Cultivate the Early Pipeline for Value Creation

Tara Nickerson, Chief Business Officer, THIRD ROCK VENTURES

 

10:30AM – 11:00AM

Networking Break

 

11:00AM – 11:45AM

Case Study: How Roivant Sciences’ Business Development Strategy Has Led to the Launch of Over a Dozen Biopharmaceutical Companies

Ruby Holder, Vice President, Investments, ROIVANT SCIENCES
Sascha Bucher, Head of Global Transactions and Head Basel Office, ROIVANT SCIENCES

11:00AM – 11:45AM

Leverage Business Development to Help Define Your Global Regulatory Strategy


William Pedranti, President, Operations, SCILEX PHARMACEUTICALS
George Ng, Executive Vice President, Chief Administrative Officer, SCILEX PHARMACEUTICALS

 

11:45AM – 12:45PM

Luncheon

12:45PM – 1:30PM

Buy- and Sell-Side Negotiation Tactics to Optimize Your Auction Process and Maximize the Value of a Deal
Timothy Herpin, Chief Business Officer, CARIBOU BIOSCIENCES
Kleem Chaudhary, Ph.D., Head BD&L MS, AD, OPN, Platforms, BIOGEN
Bethany Mancilla, Chief Business Officer and Senior Vice President, CUE BIOPHARMA

1:30PM – 2:15PM

Panel: Go Beyond the Offer — Key Questions Small Companies Should Ask When Evaluating Large Company Partners
Ruby Holder, Vice President, Business Development, ROIVANT SCIENCES
Isaac J. Bright, M.D., Chief Executive Officer, RUBRYC THERAPEUTICS
Chinmay Kanuga, Director, Scientific Assessments and Due Diligences, ALLERGAN
Peter Seufer-Wasserthal, Ph.D., Chief Business Officer, ORIGENIS